tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Globus Medical price target lowered to $90 from $97 at Canaccord

Canaccord lowered the firm’s price target on Globus Medical (GMED) to $90 from $97 and keeps a Buy rating on the shares. The firm updated its model to reflect the Q2/25 preliminary results which showed revenues in the middle of both the firm’s and the Streets consensus. The company also reaffirmed FY25 revenue to be in the the range of $2.80B-$2.90B and its guidance for EPS to be in the range $3.00-$3.30.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1